Cargando…

Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use

BACKGROUND: Dementia networks in Germany constitute a specialised setting for integrated dementia care and have shown benefits on relevant outcomes, including those of drug treatment. National guidelines recommend treatment with acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wübbeler, Markus, Wucherer, Diana, Hertel, Johannes, Michalowsky, Bernhard, Heinrich, Steffen, Meyer, Saskia, Schaefer-Walkmann, Susanne, Hoffmann, Wolfgang, Thyrian, Jochen René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460966/
https://www.ncbi.nlm.nih.gov/pubmed/25998147
http://dx.doi.org/10.1186/s12913-015-0855-7
_version_ 1782375470267891712
author Wübbeler, Markus
Wucherer, Diana
Hertel, Johannes
Michalowsky, Bernhard
Heinrich, Steffen
Meyer, Saskia
Schaefer-Walkmann, Susanne
Hoffmann, Wolfgang
Thyrian, Jochen René
author_facet Wübbeler, Markus
Wucherer, Diana
Hertel, Johannes
Michalowsky, Bernhard
Heinrich, Steffen
Meyer, Saskia
Schaefer-Walkmann, Susanne
Hoffmann, Wolfgang
Thyrian, Jochen René
author_sort Wübbeler, Markus
collection PubMed
description BACKGROUND: Dementia networks in Germany constitute a specialised setting for integrated dementia care and have shown benefits on relevant outcomes, including those of drug treatment. National guidelines recommend treatment with acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) or the N-Methyl-D-Aspartate antagonist (memantine) to reduce cognitive symptoms. However, prescription rates are lower than 30 % in general practises. This study aims to describe antidementia drug treatment and the factors that are associated with the treatment in different dementia networks across Germany. METHODS: We have analysed the socio-demographic, clinical and utilisation data from 560 patients with dementia (PWD), as well as data from their caregivers, in 13 selected dementia networks in Germany. The patients and caregivers were interviewed in their homes or in the network facilities. Multiple logistic regression models were fitted to evaluate the socio-demographic and clinical factors associated with the utilisation of antidementia drug treatment in the various networks. RESULTS: In all of the networks in the study, 52 % of the participants received an antidementia drug treatment. Factors associated with the utilisation of the antidementia drug treatment were: formal diagnosis (OR = 16.81, p < 0.001), association with a physician in the network (OR = 3.69, p < 0.001), higher number of comorbidities (OR = 0.88, p = 0.039), living alone (OR = 0.51, p = 0.032) and higher age (OR = 2.97, p = 0.002). CONCLUSION: Medical treatment of PWD with antidementia drugs in dementia networks in Germany is more frequent than in primary and nursing home care settings. Our findings also suggest that participants with a formal diagnosis and a physician in the network have increased rates of receiving antidementia drug treatments. These findings suggest that dementia networks focusing on medical treatment should support diagnostic procedures and incorporate physician specialists.
format Online
Article
Text
id pubmed-4460966
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44609662015-06-10 Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use Wübbeler, Markus Wucherer, Diana Hertel, Johannes Michalowsky, Bernhard Heinrich, Steffen Meyer, Saskia Schaefer-Walkmann, Susanne Hoffmann, Wolfgang Thyrian, Jochen René BMC Health Serv Res Research Article BACKGROUND: Dementia networks in Germany constitute a specialised setting for integrated dementia care and have shown benefits on relevant outcomes, including those of drug treatment. National guidelines recommend treatment with acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) or the N-Methyl-D-Aspartate antagonist (memantine) to reduce cognitive symptoms. However, prescription rates are lower than 30 % in general practises. This study aims to describe antidementia drug treatment and the factors that are associated with the treatment in different dementia networks across Germany. METHODS: We have analysed the socio-demographic, clinical and utilisation data from 560 patients with dementia (PWD), as well as data from their caregivers, in 13 selected dementia networks in Germany. The patients and caregivers were interviewed in their homes or in the network facilities. Multiple logistic regression models were fitted to evaluate the socio-demographic and clinical factors associated with the utilisation of antidementia drug treatment in the various networks. RESULTS: In all of the networks in the study, 52 % of the participants received an antidementia drug treatment. Factors associated with the utilisation of the antidementia drug treatment were: formal diagnosis (OR = 16.81, p < 0.001), association with a physician in the network (OR = 3.69, p < 0.001), higher number of comorbidities (OR = 0.88, p = 0.039), living alone (OR = 0.51, p = 0.032) and higher age (OR = 2.97, p = 0.002). CONCLUSION: Medical treatment of PWD with antidementia drugs in dementia networks in Germany is more frequent than in primary and nursing home care settings. Our findings also suggest that participants with a formal diagnosis and a physician in the network have increased rates of receiving antidementia drug treatments. These findings suggest that dementia networks focusing on medical treatment should support diagnostic procedures and incorporate physician specialists. BioMed Central 2015-05-22 /pmc/articles/PMC4460966/ /pubmed/25998147 http://dx.doi.org/10.1186/s12913-015-0855-7 Text en © Wübbeler et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wübbeler, Markus
Wucherer, Diana
Hertel, Johannes
Michalowsky, Bernhard
Heinrich, Steffen
Meyer, Saskia
Schaefer-Walkmann, Susanne
Hoffmann, Wolfgang
Thyrian, Jochen René
Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use
title Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use
title_full Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use
title_fullStr Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use
title_full_unstemmed Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use
title_short Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use
title_sort antidementia drug treatment in dementia networks in germany: use rates and factors associated with treatment use
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460966/
https://www.ncbi.nlm.nih.gov/pubmed/25998147
http://dx.doi.org/10.1186/s12913-015-0855-7
work_keys_str_mv AT wubbelermarkus antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse
AT wuchererdiana antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse
AT herteljohannes antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse
AT michalowskybernhard antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse
AT heinrichsteffen antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse
AT meyersaskia antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse
AT schaeferwalkmannsusanne antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse
AT hoffmannwolfgang antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse
AT thyrianjochenrene antidementiadrugtreatmentindementianetworksingermanyuseratesandfactorsassociatedwithtreatmentuse